Ascendis Pharma To Present New Data And Updated Results From Phase 1/2 IL-Believe Trial At ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma A/S (NASDAQ:ASND) presented new data and updated results from its Phase 1/2 IL-Believe Trial at ASCO 2024. The trial showed promising clinical responses in patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ, both as monotherapy and in combination with TransCon TLR7/8 Agonist.
June 03, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma presented new data from its Phase 1/2 IL-Believe Trial at ASCO 2024, showing promising clinical responses in melanoma patients treated with TransCon IL-2 β/γ.
The presentation of positive clinical trial results at a major oncology conference like ASCO is likely to boost investor confidence and positively impact the stock price of Ascendis Pharma in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100